POLIDOCANOL FOAM SCLEROTHERAPY: A BREATH OF FRESH AIR FOR THE TREATMENT OF HEMORRHOIDAL DISEASE IN PATIENTS WITH BLEEDING DISORDERS

Paulo Salgueiro

UEG Week Copenhagen 2023 | Poster

Colorectal

October 15, 2023

A prospective multicentric study of 228 patients found that polidocanol foam sclerotherapy achieved similar therapeutic success and safety for treating grades I-III hemorrhoidal disease in patients with and without bleeding disorders.

KEY POINTS

- Overall therapeutic success rate was 93.4% with no significant difference between patients with bleeding disorders (n=73) and without (n=155), despite patients with bleeding disorders presenting with higher baseline bleeding and symptom severity scores
- Patients with bleeding disorders required a higher average number of treatment sessions (1.68 vs 1.43, p=0.013) but experienced similar recurrence rates and complication rates compared to patients without bleeding disorders
- The overall complication rate was 11.4%, with 96.2% classified as mild and bleeding complications occurring in only 4.8% of patients across both groups
- Patients with congenital bleeding disorders did not receive prior bleeding prophylaxis and those on antithrombotic drugs did not discontinue therapy, yet no increased thrombotic risk was observed with polidocanol foam sclerotherapy

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/03ff84fa-743c-11ee-85d0-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.